Yahoo · Nov 10, 2026
Bicara Therapeutics Inc (BCAX) Q3 2026 Earnings Call Highlights: Strong Enrollment Momentum and ...
Bicara Therapeutics Inc (BCAX) advances its pivotal FORTIFY-HN01 study toward a mid-2027 interim readout while reporting durable Phase 1b responses and a cash runway extending into 2029.

